Elutia Inc. - ELUT STOCK NEWS

Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the LD Micro Main Event XVII Conference in Los Angeles. Dr. Randy Mills, President and CEO, will deliver a presentation on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). The company's management team will also be available for one-on-one meetings with institutional investors, who can schedule appointments through LD Micro representatives or by contacting IR@elutia.com.

Elutia Inc. (ELUT) announced positive preclinical data for EluPro, the first FDA-cleared antibiotic-eluting biologic envelope for implantable devices. Published in Frontiers in Drug Delivery, the study showed EluPro's effectiveness in clearing bacterial contamination associated with cardiovascular implantable electronic devices (CIEDs). In a rabbit model, EluPro demonstrated complete eradication of MRSA and other bacterial strains with minimal systemic antibiotic exposure.

EluPro received FDA clearance for use with CIEDs in June 2024 and has been approved for additional devices. The first patient implant was completed in September 2024. Elutia is preparing for EluPro's commercial launch in January 2025.

Elutia Inc. (Nasdaq: ELUT) is celebrating its first anniversary since rebranding on September 6, 2023. The company, which focuses on drug-eluting biomatrix products, has achieved significant milestones in its inaugural year:

• Secured FDA approval for EluPro™, the first Antibiotic-Eluting BioEnvelope
• Successfully completed an FDA inspection of their manufacturing facility
• Implanted the first EluPro envelope on September 5, 2024
• Grew proprietary product sales by 20%
• Increased shareholder value by over 170%

The company's leadership expressed gratitude to stakeholders, partners, and employees for their contributions to Elutia's remarkable growth and accomplishments.

Elutia Inc. (Nasdaq: ELUT) has announced the first patient implant of EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac pacemakers and neurostimulators. The procedure was performed by Dr. John Catanzaro at East Carolina University Health Medical Center. EluPro is designed to prevent post-operative complications in patients with implantable devices.

Cleared by the FDA in June 2024, EluPro targets the $600 million U.S. implantable electronic device protection market. Elutia aims to establish a presence in the $8 billion cardiac rhythm management market and adjacent $8 billion neurostimulation sectors. The full commercial launch of EluPro is scheduled for January 2025.

Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix products, has announced its participation in two upcoming investor conferences in New York. Dr. Randy Mills, President and CEO, and Matt Ferguson, CFO, will represent the company at these events:

1. H.C. Wainwright 26th Annual Global Investment Conference:
- Presentation available on-demand from September 9, 2024, 7:00 a.m. ET
- One-on-one meetings on September 11, 2024

2. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference:
- One-on-one meetings on September 12, 2024

Institutional investors can arrange meetings with Elutia's management through their H.C. Wainwright and Lake Street representatives.

Elutia (Nasdaq: ELUT) announced its financial results for Q2 2024. Key highlights include FDA clearance for EluPro, the first antibiotic-eluting BioEnvelope for implantable electronic devices, and a successful FDA inspection of its manufacturing facility. The company has commenced EluPro's production and expanded its commercial team. Financially, net sales were steady at $6.3 million. CanGaroo and SimpliDerm sales rose by 19% and 7% respectively, while cardiovascular product sales dropped 38%. Gross margin improved to 45% from 43%. However, total operating expenses increased to $11.3 million, resulting in a higher net loss of $28.2 million, primarily due to a non-cash charge of $18.3 million related to warrant revaluation. Adjusted EBITDA showed an improved loss of $2.9 million. The cash balance stood at $18.2 million, not including $13.8 million from warrant exercises post-quarter.

Elutia Inc. (Nasdaq: ELUT) has announced the full exercise of warrants from a September 2023 private placement, generating $15.7 million in gross proceeds. This financial boost strengthens Elutia's balance sheet, supporting the launch of EluPro®, the world's first FDA-cleared antibiotic-eluting BioEnvelope. CEO Dr. Randy Mills emphasized the significance of this capital injection, attributing it to the substantial shareholder value created over the past year.

The private placement involved the sale of 7,355,869 shares of common stock (or pre-funded warrants) and 11,033,804 warrants at $1.4275 per share and associated warrants. All non-pre-funded common stock warrants have been exercised. Lake Street Capital Markets, served as the exclusive placement agent for this transaction.

Elutia Inc. (Nasdaq: ELUT) has appointed Ryan Marques, Ph.D., MBA as Vice President of Operations. Dr. Marques brings over 20 years of experience in leading operations teams across manufacturing, quality assurance, supply chain, and technical services in the device and pharmaceutical industries. This appointment comes as Elutia prepares to launch EluPro®, the world's first FDA-cleared antibiotic-eluting BioEnvelope, in the second half of 2024.

Dr. Marques previously served as Head of U.S. Operations at Nobelpharma America and has held leadership positions at Next Breath Inc./Aptar Pharma and Canon BioMedical. He holds a Ph.D. in Molecular Microbiology and Immunology and an MBA from the University of Maryland. His expertise is expected to be instrumental in Elutia's growth and product expansion.

Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced it will release its second quarter 2024 financial results after market close on Wednesday, August 7, 2024. The company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Investors can access the conference call through a webcast or by phone using the following details:

• U.S. Investors: 877-407-8029
• International Investors: 201-689-8029
• Conference ID: 13747696

A live and archived webcast of the event will be available on the 'Investors' section of the Elutia website at https://investors.elutia.com/.